Stock LILY34 ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eli Lilly and Company Sao Paulo

Equities

LILY34

BRLILYBDR006

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 16:05:00 2024-06-28 EDT 		5-day change 1st Jan Change
169 BRL +1.86% Intraday chart for Eli Lilly and Company +3.00% +80.92%
06-28 Atossa Therapeutics Doubles Z-Endoxifen Dose in Phase 2 Breast Cancer Study MT
06-28 EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 126,190 153,067 250,419 347,613 524,224 815,209 - -
Enterprise Value (EV) 1 139,069 165,981 263,395 361,640 546,522 834,118 831,268 823,778
P/E ratio 14.8 x 24.9 x 45.1 x 53 x 101 x 67.7 x 48.5 x 37.7 x
Yield 1.96% 1.75% 1.23% 1.07% 0.78% 0.57% 0.66% 0.75%
Capitalization / Revenue 5.65 x 6.24 x 8.84 x 12.2 x 15.4 x 19 x 15.5 x 13.1 x
EV / Revenue 6.23 x 6.76 x 9.3 x 12.7 x 16 x 19.4 x 15.8 x 13.2 x
EV / EBITDA 18.4 x 19.3 x 26.3 x 38.2 x 63.7 x 51.4 x 37.6 x 29.1 x
EV / FCF 36.6 x 32.5 x 44.3 x 69.1 x 690 x 105 x 62.6 x 45.7 x
FCF Yield 2.73% 3.08% 2.26% 1.45% 0.15% 0.95% 1.6% 2.19%
Price to Book 48.3 x 28.6 x 29.4 x 32.7 x 48.9 x 45.6 x 28 x 18.7 x
Nbr of stocks (in thousands) 960,131 906,582 906,592 950,178 899,307 900,405 - -
Reference price 2 131.4 168.8 276.2 365.8 582.9 905.4 905.4 905.4
Announcement Date 20-01-30 21-01-29 22-02-03 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,320 24,540 28,318 28,541 34,124 42,973 52,681 62,254
EBITDA 1 7,551 8,589 10,005 9,472 8,584 16,230 22,085 28,272
EBIT 1 6,079 7,265 8,457 7,950 7,057 14,683 20,125 25,772
Operating Margin 27.24% 29.6% 29.86% 27.85% 20.68% 34.17% 38.2% 41.4%
Earnings before Tax (EBT) 1 5,266 7,230 6,156 6,806 6,555 13,749 18,799 22,948
Net income 1 8,318 6,194 5,582 6,245 5,240 11,932 16,631 21,438
Net margin 37.27% 25.24% 19.71% 21.88% 15.36% 27.77% 31.57% 34.44%
EPS 2 8.890 6.790 6.120 6.900 5.800 13.37 18.68 24.00
Free Cash Flow 1 3,803 5,112 5,951 5,230 792.5 7,918 13,284 18,025
FCF margin 17.04% 20.83% 21.01% 18.32% 2.32% 18.43% 25.22% 28.95%
FCF Conversion (EBITDA) 50.36% 59.52% 59.48% 55.21% 9.23% 48.79% 60.15% 63.75%
FCF Conversion (Net income) 45.71% 82.53% 106.61% 83.75% 15.12% 66.36% 79.87% 84.08%
Dividend per Share 2 2.580 2.960 3.400 3.920 4.520 5.192 5.993 6.763
Announcement Date 20-01-30 21-01-29 22-02-03 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8,000 7,810 6,488 6,942 7,302 6,960 8,312 9,499 9,353 8,768 10,000 11,327 12,781 10,920 12,135
EBITDA 1 2,982 3,046 1,679 2,373 2,375 1,982 2,618 986.4 2,855 3,049 3,750 4,844 5,994 - -
EBIT 1 2,536 2,610 1,330 2,010 2,000 1,620 2,252 575.4 2,468 2,648 3,078 3,976 4,812 - -
Operating Margin 31.7% 33.42% 20.5% 28.96% 27.39% 23.27% 27.09% 6.06% 26.38% 30.2% 30.78% 35.1% 37.65% - -
Earnings before Tax (EBT) 1 - - - - - - 2,089 427.2 2,509 2,536 3,000 3,878 4,496 - -
Net income 1 1,726 1,903 952.5 1,452 1,938 1,345 1,763 -57.4 2,190 2,243 2,477 3,249 4,025 - -
Net margin 21.58% 24.36% 14.68% 20.91% 26.54% 19.32% 21.21% -0.6% 23.41% 25.58% 24.77% 28.68% 31.49% - -
EPS 2 1.900 - 1.050 1.610 2.140 1.490 1.950 -0.0600 2.420 2.480 2.774 3.603 4.459 - -
Dividend per Share 2 0.8500 0.9800 0.9800 0.9800 0.9800 1.130 1.130 1.130 1.130 1.300 1.300 1.300 1.299 - -
Announcement Date 22-02-03 22-04-28 22-08-04 22-11-01 23-02-02 23-04-27 23-08-08 23-11-02 24-02-06 24-04-30 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,879 12,914 12,976 14,027 22,298 18,909 16,059 8,569
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.706 x 1.504 x 1.297 x 1.481 x 2.598 x 1.165 x 0.7272 x 0.3031 x
Free Cash Flow 1 3,803 5,112 5,951 5,230 793 7,918 13,284 18,025
ROE (net income / shareholders' equity) 89.6% 175% 102% 73.2% 48.9% 82.6% 73.5% 65.4%
ROA (Net income/ Total Assets) 13.4% 14.4% 15.6% 14.6% 9.23% 17.6% 21.3% 24.7%
Assets 1 62,143 42,961 35,816 42,708 56,748 67,700 78,039 86,890
Book Value Per Share 2 2.720 5.900 9.410 11.20 11.90 19.90 32.30 48.40
Cash Flow per Share 2 5.170 7.120 7.960 7.830 4.690 15.40 20.00 25.20
Capex 1 1,034 1,388 1,310 1,854 3,448 3,555 3,007 3,123
Capex / Sales 4.63% 5.66% 4.63% 6.5% 10.1% 8.27% 5.71% 5.02%
Announcement Date 20-01-30 21-01-29 22-02-03 23-02-02 24-02-06 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4 USD
Average target price
868.9 USD
Spread / Average Target
-4.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. LILY34 Stock
  5. Financials Eli Lilly and Company